Semaglutide STEP 1: a lesson in trial design
Use a large human trial to practise reading the population, comparison, outcomes and limits together.
Population and comparison
The 2021 STEP 1 report enrolled 1,961 adults with overweight or obesity who did not have diabetes. It used random assignment, double blinding and a placebo comparator over 68 weeks. Both groups also received a lifestyle intervention. Those details define the question tested.
Read benefits and harms together
The primary outcomes concerned body-weight change and the proportion reaching a specified weight-loss threshold. The paper also reported adverse events and treatment discontinuation, including gastrointestinal events. A reading focused only on the headline result misses part of the evidence.
Where the result stops
The trial evaluated its specified intervention in its enrolled population. It did not test every formulation or product carrying the semaglutide name, nor every patient group or lifetime outcome. The paper names Novo Nordisk as funder. This is a study-design example, not a product comparison or treatment recommendation.
Follow the sources
- 1Once-Weekly Semaglutide in Adults with Overweight or Obesity Primary randomized human trial, 2021